Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

• Published in: Prostaglandins, leukotrienes and essential fatty acids Vol. 92; pp. 63 - 65
• Main Authors: Lagarde, M, Hachem, M, Bernoud-Hubac, N, Picq, M, Véricel, E, Guichardant, M
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.01.2015; Elsevier
• Subjects: Advanced Basic Science; Animals; Blood–brain barrier; Brain - drug effects; Brain - metabolism; Brain - pathology; Endocrinology & Metabolism; Food and Nutrition; Humans; Life Sciences; Metabolism; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Phosphatidylcholines - pharmacology; Phosphatidylcholines - therapeutic use; Phospholipids - metabolism; Stroke; Stroke - drug therapy; Metabolism; Stroke; Blood–brain barrier; blood-brain barrier; stroke; metabolism
• ISSN: 0952-3278; 1532-2823
• DOI: 10.1016/j.plefa.2014.01.005

Abstract 1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.